Lower GI 2016

The Royal Marsden

When is it important to know?

• Patients undergoing major radical surgery with curative intent: e.g. ELAPE/ extenteration • Oligometastatic disease – potentially resectable vs widespread metastatic disease • Synchronous metastatic disease control – liver first/ primary first?

• Type and duration of adjuvant chemotherapy • Biomarker for resistance to 1 st line chemotherapy • Unexplained rise in CEA level